secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001771910-25-000006
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%
--------------------------------------------------------------------------------

- Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.
- Completed $100M PIPE with $93.1M net proceeds; cash $264.6M, expected runway into 2028.
- LOTIS-7 (ZYNLONTA+glofitamab) showed 93.3% ORR, 86.7% CR in r/r DLBCL; expansion to 100 patients underway.
- Strategic restructuring: discontinuing early solid tumor programs, shutting UK facility, workforce reduction ~30% by Sep 2025.
- LOTIS-5 Phase 3 on track to reach PFS events by end of 2025; sBLA filing expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/0001771910-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/adc-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001771910-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer